Skip to content
Screener

Aurinia Pharmaceuticals AUPH Q3 2025 earnings

Reported November 4, 2025 · Before market open

Revenue$73.5MMiss by $1.2M
EPS$0.23Beat by $0.07
Revenue estimate$74.7M
EPS estimate$0.16

Next report

Nov 3, 2026 (in 2 months)
Revenue estimate$83.6M
EPS estimate$0.21

Financials

Q3 2025

Income statement

See full
Revenue$73.5M+8.4%
Gross profit$65.3M+5.8%
Operating income$29.7M+153%
Net income$31.6M+120%
EPS (diluted)$0.23+130%

Balance sheet

See full
Cash & equivalents$73.2M+97.1%
Total debt$94.5M-8.0%
Total equity$365.8M-5.7%
Total assets$527.5M-4.0%

Cash flow

See full
Operating cash flow$44.4M+161%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$1.45B+38.7%
Enterprise value$1.48B+32.5%
P/E18.7×—
P/S5.5×+0.7×

Profitability

See full
Gross margin88.9%+1.7pp
Operating margin26.3%+19.4pp
Net margin29.3%+23.3pp

Returns & leverage

See full
Return on equity20.7%+16.9pp
Debt / equity0.3×0.0×
Current ratio5.8×+0.2×

Segments

By product

See full
License, collaboration and royalty revenue$2.8M—

FAQ

When did Aurinia Pharmaceuticals report Q3 2025 earnings?
Aurinia Pharmaceuticals (AUPH) reported Q3 2025 earnings on November 4, 2025 before market open.
What were Aurinia Pharmaceuticals's Q3 2025 revenue and EPS?
Aurinia Pharmaceuticals reported revenue of $73.5M and eps of $0.23 for Q3 2025.
Did Aurinia Pharmaceuticals beat estimates in Q3 2025?
Revenue missed the consensus estimate of $74.7M by $1.2M. EPS beat the consensus estimate of $0.16 by $0.07.
How did Aurinia Pharmaceuticals's Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 8.4% from $67.8M a year earlier and eps grew 130.0% from $0.10.
Where can I find Aurinia Pharmaceuticals's Q3 2025 SEC filings?
You can read the 8-K earnings release (0001600620-25-000108) and the 10-Q periodic report (0001600620-25-000106) directly on SEC EDGAR. The filing index links above go to sec.gov.